Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Picard Medical Inc. (NASDAQ: PMI)

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants Picard Medical Inc., Patrick NJ Schnegelsberg, Matt Schuster, Yuncai “Richard” Fang, Chris Hsieh, Westpark Capital, Inc., Sentinel Brokers Company, Inc., R.F. Lafferty & Co. Inc., American Trust Investments, and MaloneBailey, LLP (collectively, the “Defendants”). The action, which was filed in the U.S. District Court for the Northern District of California and captioned Louie v. Picard Medical, Inc. et al., Case No. 5:26-cv-01024, asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased Picard Medical Securities (“PMI”) between September 2, 2025, and October 31, 2025, inclusive (the “Class Period”), and who were damaged thereby. The lead plaintiff deadline in this action is April 3, 2026.

LEAD PLAINTIFF DEADLINE ON APRIL 3, 2026

Picard Medical claims to engage in designing, manufacturing, production, supply, marketing, and sale of medical device products. Their website details their most significant product is an artificial heart called “SynCardia TAH.” The company is headquartered in Tucson, Arizona, with operations in the United States, Europe, and China.

The complaint alleges that Defendants violated provisions of the Securities Act by making materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and the true nature of the trading activity in its securities. The complaint alleges that Defendants were uniquely situated to orchestrate a pump-and-dump scheme on its class A ordinary shares. After plaintiffs and class members purchased PMI, the complaint alleges that Picard’s stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Picard in online forums, chat groups, and through social media posts with sensational but baseless claims to create a buying frenzy among retail investors.

LEAD PLAINTIFF DEADLINE ON APRIL 3, 2026

If you purchased Picard Medical Securities between September 2, 2025, and October 31, 2025, inclusive, and have suffered significant losses, realized or unrealized, you are encouraged to contact Scott+Scott attorney Mollie Chadwick at (619) 233-4565, or via email at mchadwick@scott-scott.com, for more information.

The lead plaintiff deadline in this action is April 3, 2026. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2026. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain a member of the proposed class.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiffs’ counsel, Mollie Chadwick at (619) 233-4565, or via email at mchadwick@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoing, including securities law and shareholder violations.

With 150 attorneys plus supporting staff in eight offices in the United States as well as one office in Canada and three in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief.

Our attorneys have been recognized across legal publications, including by Lawdragon for being among the 500 Top Financial Lawyers and the 500 Leading Global Antitrust & Competition Lawyers. In addition, we have received top rankings by WWL: Commercial Litigation, Legal 500 in Antitrust as well as Securities Litigation, Chambers, and Best Lawyers®. Our attorneys have been repeatedly recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States.

To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit www.scott-scott.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260203158187/en/

Scott+Scott Attorneys at Law LLP is investigating the sudden collapse of Picard Medical’s stock in late October 2025, following a dramatic yet illusory run-up orchestrated by a fraudulent stock promotion scheme.